Home > Insider Trading > Filing (0000899243-18-024796)

Filing Details

Accession Number:: 0000899243-18-024796
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-09-19 19:42:01
Reporting Period:: 2018-09-17

Accepted Time:: 2018-09-19 19:42:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492422	Apellis Pharmaceuticals Inc.	APLS	Pharmaceutical Preparations (2834)	271537290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1543112	Ltd Investments Venture Morningside	2Nd Floor, Le Prince De Galles 3-5 Avenue Des Citronniers Mc 98000 O9		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-09-17	31,400	$18.50	11,384,703	No	4	P	Direct
Common Stock	Acquisiton	2018-09-17	8,600	$18.84	11,393,303	No	4	P	Direct
Common Stock	Acquisiton	2018-09-18	40,000	$18.47	11,433,303	No	4	P	Direct
Common Stock	Acquisiton	2018-09-19	60,000	$18.09	11,493,303	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $17.75 to $18.74, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $18.75 to $18.99, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were purchased on 9/18/2018 in multiple transactions at prices ranging from $18.23 to $18.96, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were purchased on 9/19/2018 in multiple transactions at prices ranging from $17.81 to $18.44, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL.